NCT06032741 is a clinical trial in Guillain-Barre Syndrome, sponsored by First Affiliated Hospital of Wenzhou Medical University.

Who is sponsoring NCT06032741?

NCT06032741 is sponsored by First Affiliated Hospital of Wenzhou Medical University.

What condition does NCT06032741 study?

NCT06032741 studies Guillain-Barre Syndrome.

Is NCT06032741 still recruiting?

NCT06032741 is currently status unknown. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT06032741

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognosis in Patients With Guillain-Barre Syndrome

Status unknown Last updated 13 September 2023

What this trial tests

trial in Guillain-Barre Syndrome in 450 participants. Status unknown.

Timeline

2 January 2013

Primary endpoint
1 December 2022

31 January 2025

Quick facts

Lead sponsor	First Affiliated Hospital of Wenzhou Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	2 January 2013
Primary completion	1 December 2022
Estimated completion	31 January 2025
Sites	1 location across China

Conditions studied

Guillain-Barre Syndrome — all drugs for Guillain-Barre Syndrome →

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Who can join

Eligibility, any sex, with Guillain-Barre Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Guillain-Barre Syndrome

Currently open trials in the same condition.

NCT07020819 — An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barr · Phase 3 · recruiting

Other First Affiliated Hospital of Wenzhou Medical University trials

Trials by the same sponsor.

NCT07394205 — Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Can · EARLY_PHASE1 · not yet recruiting
NCT07179120 — Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm · Phase 2 · not yet recruiting
NCT07495735 — Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellula · not yet recruiting
NCT07381634 — The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities · Phase 2 · not yet recruiting
NCT07284524 — Intelligent Precision Knee Preservation System for Knee Osteoarthritis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06032741 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Wenzhou Medical University
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06032741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing